Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · VRTX · as of Jun 8, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
84
12 Months
Buy/Sell ratio
0.05
Buy/Sell (by trades)
Overall sentiment
Vertex Pharmaceuticals Incorporated insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
VRTX insider buying and selling by quarter
VRTX insider selling · VRTX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · VRTX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
VRTX executive sell shares · VRTX board member insider trading · VRTX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 29, 2026 | Bozic Carmen EVP and CMO | Sale | 1,974 | $888K | Form 4 |
| May 15, 2026 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale | 33 | $15K | Form 4 |
| May 15, 2026 | Bozic Carmen EVP and CMO | Sale | 1,354 | $614K | Form 4 |
| May 12, 2026 | Bozic Carmen EVP and CMO | Sale | 6,988 | $3.14M⚡ | Form 4 |
| May 1, 2026 | Upadhyay Suketu Director | Other | 796 | — | Form 4 |
| May 1, 2026 | Thornberry Nancy Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Thornberry Nancy Director | Other | 398 | — | Form 4 |
| May 1, 2026 | Schneider Jennifer Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Schneider Jennifer Director | Other | 796 | — | Form 4 |
| May 1, 2026 | MCKENZIE DIANA Director | Award | 943 | — | Form 4 |
| May 1, 2026 | MCKENZIE DIANA Director | Other | 796 | — | Form 4 |
| May 1, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 1,104 | $469K | Form 4 |
| May 1, 2026 | Garber Alan M Director | Award | 472 | — | Form 4 |
| May 1, 2026 | Bhatia Sangeeta N. Director | Award | 943 | — | Form 4 |
| May 4, 2026 | Bhatia Sangeeta N. Director | Sale | 318 | $135K | Form 4 |
| Apr 1, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 978 | $439K | Form 4 |
| Mar 27, 2026 | Bozic Carmen EVP and CMO | Sale | 2,329 | $1.05M⚡ | Form 4 |
| Mar 13, 2026 | Bozic Carmen EVP and CMO | Sale | 2,329 | $1.12M⚡ | Form 4 |
| Mar 11, 2026 | McKechnie Duncan EVP, Chief Commercial Officer | Sale | 2,633 | $1.31M⚡ | Form 4 |
| Mar 4, 2026 | McKechnie Duncan EVP, Chief Commercial Officer | Sale | 2,437 | $1.16M⚡ | Form 4 |
| Mar 2, 2026 | Liu Joy EVP and Chief Legal Officer | Sale | 892 | $442K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 400 | $192K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 120 | $58K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 240 | $116K | Form 4 |
| Feb 27, 2026 | Kewalramani Reshma CEO & President · Director | Sale | 2,510 | $1.22M⚡ | Form 4 |
Bunnage Mark E.
EVP, Chief Scientific Officer
Date
May 15
Shares
33
Price
$453.45
Value
$15K
Liu Joy
EVP and Chief Legal Officer
Date
May 1
Shares
1,104
Price
$425.02
Value
$469K
Liu Joy
EVP and Chief Legal Officer
Date
Apr 1
Shares
978
Price
$449.17
Value
$439K
McKechnie Duncan
EVP, Chief Commercial Officer
Date
Mar 11
Shares
2,633
Price
$498.42
Value
$1.31M ⚡
McKechnie Duncan
EVP, Chief Commercial Officer
Date
Mar 4
Shares
2,437
Price
$475.30
Value
$1.16M ⚡
Liu Joy
EVP and Chief Legal Officer
Date
Mar 2
Shares
892
Price
$495.96
Value
$442K
Kewalramani Reshma
CEO & President · Director
Date
Feb 27
Shares
400
Price
$479.75
Value
$192K
Kewalramani Reshma
CEO & President · Director
Date
Feb 27
Shares
120
Price
$481.50
Value
$58K
Kewalramani Reshma
CEO & President · Director
Date
Feb 27
Shares
240
Price
$482.84
Value
$116K
Kewalramani Reshma
CEO & President · Director
Date
Feb 27
Shares
2,510
Price
$487.13
Value
$1.22M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About VRTX insider trading
VRTX insider trades
Vertex Pharmaceuticals Incorporated (VRTX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Kewalramani Reshma (CEO & President · Director), Sachdev Amit (EVP Chief Patient & Ext Af Off), Bozic Carmen (EVP and CMO). Over the past 12 months, 5 insiders have filed transactions with the SEC. VRTX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Vertex Pharmaceuticals Incorporated's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
VRTX insider trading · 5 questionsThe insiders of Vertex Pharmaceuticals Incorporated (VRTX) include executives and directors such as Kewalramani Reshma (CEO & President · Director), Sachdev Amit (EVP Chief Patient & Ext Af Off), Bozic Carmen (EVP and CMO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026